Tirzepatide Clinical Trials
26 actively recruiting trials across 14 locations
Also known as: GIP/GLP-1RA, LY3298176, LY3298176 (development code name), Mounjaro, Mounjaro (brand name in certain regions), Spartina, Tirzepatide 5、10、15mg, ZepBound, Zepbound, Zepbound (brand name in certain regions), Zepbound, LY3298176
Other11 trials
San Antonio, Texas2 trials
University Health System Texas Diabetic Institute
University of Texas Health Science Center at San Antonio
Tuscaloosa, Alabama1 trial
Avondale, Arizona1 trial
AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale
Duarte, California1 trial
Tarzana, California1 trial
Tarzana Treatment Centers
Torrance, California1 trial
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute)
Miami, Florida1 trial
Honolulu, Hawaii1 trial
John A Burns School of Medicine
Boston, Massachusetts1 trial
Massachusetts General Hospital Cancer Center
Basking Ridge, New Jersey1 trial
Memorial Sloan Kettering Basking Ridge
Elizabeth, New Jersey1 trial
Trinitas Comprehensive Cancer Center
Cleveland, Ohio1 trial
Dallas, Texas1 trial
Baylor University Medical Center, Baylor Charles A Sammons Cancer Center
Houston, Texas1 trial
The University of Texas M. D. Anderson Cancer Center
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.